Long noncoding RNA GACAT3 promotes glioma progression by sponging miR‐135a

Wang, Jing; Zhang, Ming; Lu, Weifeng

doi:10.1002/jcp.27946

Cited by 19 publications

(26 citation statements)

References 21 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, our data identified LINC00526 as a potential prognostic biomarker for glioma and suggested that ectopic expression of LINC00526 may be a potential therapeutic strategy for glioma. LncRNAs GAS5, NEAT1, GACAT3, CASC9, HMMR‐AS1, LINC00152, HOTAIRM1, AC003092.1, HOXD‐AS1, OIP5‐AS1, DANCR and so on have been reported to play oncogenic or tumour suppressive roles in glioma . Our study further proved the critical roles of lncRNAs in glioma and provided another candidate lncRNA for glioma prognosis and therapy.…”

Section: Discussionsupporting

confidence: 63%

Long non‐coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL

Yan

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Glioma is the most common primary intracranial carcinoma with extremely poor prognosis. The significances of long non‐coding RNA (lncRNA) involved in glioma have been started revealed. However, the expression, roles and molecular mechanisms of most lncRNAs in glioma are still unknown. In this study, we identified a novel lncRNA LINC00526, which is significantly low expressed in glioma. Low expression of LINC00526 is correlated with aggravation and poor survival in glioma. Functional assays revealed that ectopic expression of LINC00526 inhibits glioma cell proliferation, migration, and invasion. LINC00526 silencing promotes glioma cell proliferation, migration and invasion. Mechanistically, we found that LINC00526 directly interacts with EZH2, represses the binding of EZH2 to AXL promoter, attenuates the transcriptional activating roles of EZH2 on AXL , and therefore represses AXL expression. Via repressing AXL, LINC00526 further represses PI3K/Akt/NF‐κB signalling. Intriguingly, we identified that NFKB1 and NFKB2 directly binds LINC00526 promoter and represses LINC00526 transcription. We further found that via activating NF‐κB signalling, AXL represses LINC00526 transcription. Therefore, LINC00526/EZH2/AXL/PI3K/Akt/NF‐κB form a feedback loop in glioma. Analysis of the TCGA data revealed that the expression of LINC00526 is inversely correlated with that of AXL in glioma tissues. In addition, functional rescue assays revealed that the tumour suppressive roles of LINC00526 are dependent on the negative regulation of AXL. Collectively, our data identified LINC00526 as a tumour suppressor in glioma via forming a double negative feedback loop with AXL. Our data also suggested LINC00526 as a potential prognostic biomarker and therapeutic candidate for glioma.

show abstract

Section: Discussionsupporting

confidence: 63%

Long non‐coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL

Yan

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Overexpression of GACAT3 in lung cancer cells promoted cell proliferation and migration (13), and it enhanced their sensitivity to radiotherapy. GACAT3 was recently demonstrated to promote progression of colorectal cancer (14), breast cancer (15), and glioma (16,17). However, the role of GACAT3 in HCC remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of a Prognostic lncRNA Signature for Hepatocellular Carcinoma

Chen

Huang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: An accumulating body of evidence suggests that long non-coding RNAs (lncRNAs) can serve as potential cancer prognostic factors. However, the utility of lncRNA combinations in estimating overall survival (OS) for hepatocellular carcinoma (HCC) remains to be elucidated. This study aimed to construct a powerful lncRNA signature related to the OS for HCC to enhance prognostic accuracy. Methods: The expression patterns of lncRNAs and related clinical data of 371 HCC patients were obtained based on The Cancer Genome Atlas (TCGA). Differentially expressed lncRNAs (DElncRNAs) were acquired by comparing tumors with adjacent normal samples. lncRNAs displaying significant association with OS were screened through univariate Cox regression analysis and the least absolute shrinkage and selection operator (LASSO) algorithm. All cases were classified into the validation or training group at the ratio of 3:7 to validate the constructed lncRNA signature. Data from the Gene Expression Omnibus (GEO) were used for external validation. We conducted real-time polymerase chain reaction (PCR) and assays for Transwell invasion, migration, CCK-8, and colony formation to determine the biological roles of lncRNA. Gene set enrichment analysis (GSEA) of the lncRNA model risk score was also conducted. Results: We identified 1292 DElncRNAs, among which 172 were significant in univariate Cox regression analysis. In the training group (n = 263), LASSO regression analysis confirmed 11 DElncRNAs including AC010547.1, AC010280.2, AC015712.7, GACAT3 (gastric cancer associated transcript 3), AC079466.1, AC089983.1, AC051618.1, AL121721.1, LINC01747, LINC01517, and AC008750.3. The prognostic risk score was calculated, and the constructed risk model showed significant correlation with HCC OS (log-rank P-value of 8.489e-9, hazard ratio of 3.648, 95% confidence interval: 2.238-5.945). The area under the curve (AUC) for this lncRNA model was up to 0.846. This risk model was confirmed in the validation group (n = 108), the entire cohort, and the external GEO dataset (n = 203). GACAT3 was highly expressed in HCC tissues and cell lines. Based on online databases, GACAT3 expression independently affects both Li et al. Prognostic lncRNA Signature for HCC OS and disease-free survival in HCC patients. Silencing GACAT3 in vitro significantly suppressed HCC cell proliferation, invasion, and migration. Moreover, pathways related to the lncRNA model risk score were confirmed by GSEA. Conclusion: The lncRNA signature established in this study can be used to predict HCC prognosis, which could provide novel clinical evidence to guide targeted HCC treatment.

show abstract

“…Bioinformatics analysis revealed two complementary sites of miR-135a in UCA1, and a luciferase activity assay confirmed that miR-135a was a target of UCA1 and was decreased by UCA1 46 . Similarly, GACAT3 decreased miR-135a expression by acting as a ceRNA 47 , similar to FOXD3-AS1 and MBNL1-AS1 48 , 50 . MiR-135a is also sponged by SNHG16, and this process is promoted by activation of the JAK2/STAT3 pathway 51 .…”

Section: Mechanisms Of Mir-135a Dysregulation In Cancermentioning

confidence: 82%

“…Other studies have shown that miR-135a is also regulated by interactions with long non-coding RNAs (lncRNAs), such as urothelial carcinoma associated 1 (UCA1) 46 , gastric cancer associated transcript 3 (GACAT3) 47 , FOXD3 antisense RNA 1 (FOXD3-AS1) 48 , differentiation antagonizing nonprotein coding RNA (DANCR) 49 , muscleblind-like 1 antisense RNA 1 (MBNL1-AS1) 50 , and the small nucleolar RNA host gene 16 (SNHG16) 51 . These lncRNAs act as competing endogenous RNAs (ceRNAs) by binding to miRNAs via miRNA response elements 52 .…”

Section: Mechanisms Of Mir-135a Dysregulation In Cancermentioning

confidence: 99%

MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy

Cao¹,

Qiu²,

Ye³

et al. 2020

Cancer Biol. Med.

View full text Add to dashboard Cite

Long noncoding RNA GACAT3 promotes glioma progression by sponging miR‐135a

Cited by 19 publications

References 21 publications

Long non‐coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL

Long non‐coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL

Identification and Validation of a Prognostic lncRNA Signature for Hepatocellular Carcinoma

MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy

Contact Info

Product

Resources

About